Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 10;8(4):141-145.
doi: 10.4103/JMAU.JMAU_63_20. eCollection 2020 Oct-Dec.

COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors

Hayder M Al-Kuraishy  1 , Ali I Al-Gareeb  1 , Marwa S Al-Niemi  2 , Ali K Al-Buhadily  1 , Nasser A Al-Harchan  3 , Claire Lugnier  4
Affiliations
Review

COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors

Hayder M Al-Kuraishy et al. J Microsc Ultrastruct. .

Abstract

COVID-19 pathology is mainly associated to a pulmonary disease which sometimes might result in an uncontrollable storm related to inflammatory diseases which could be fatal. It is well known that phosphodiesterase enzyme type 5 inhibitors (PDE5Is), such as sildenafil, have been successfully developed for the treatment of pulmonary arterial hypertension; interestingly, more recently, it was shown that PDE5Is might be also anti-inflammatory. Therefore, it would be of interest to question about the use of PDE5Is to overcome the COVID-19 storm, as much as PDE5 is mainly present in the lung tissues and vessels.

Keywords: Acute lung injury; COVID-19; nucleotide phosphodiesterase enzyme.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Genomic structure of severe acute respiratory syndrome coronavirus 2
Figure 2
Figure 2
Pathogenesis of severe acute respiratory syndrome coronavirus 2
Figure 3
Figure 3
Pathophysiology of severe acute respiratory syndrome coronavirus 2 in acute respiratory distress syndrome[14]
Figure 4
Figure 4
Systemic inflammations and multiorgan injury during severe acute respiratory syndrome coronavirus
See this image and copyright information in PMC

References

    1. AL-KURAISHY HM, Al-Gareeb AI. Is ivermectin–Azithromycin combination the next step for COVID-19.? Biomedical and Biotechnology Research Journal (BBRJ) 2020;45:101.
    1. AL-KURAISHY HM, Al-Gareeb AI. Macrolides and COVID-19: An optimum premise. Biomedical and Biotechnology Research Journal (BBRJ) 2020;43:189.
    1. Saif LJ, Wang Q, Vlasova AN, Jung K, Xiao S. Coronaviruses. Dis Swine. 2019;66:488–523.
    1. Ceccarelli M, Berretta M, Rullo EV, Nunnari G, Cacopardo B. Editorial-differences and similarities between severe acute respiratory syndrome (SARS)-coronavirus (CoV) and SARS-CoV-2.Would a rose by another name smell as sweet. Eur Rev Med Pharmacol Sci. 2020;24:2781–3. - PubMed
    1. Ji HL, Zhao R, Matalon S, Matthay MA. Elevated plasmin (ogen) as a common risk factor for COVID-19 susceptibility. Physiol Rev. 2020;100:1065–75. - PMC - PubMed